Related Experiment Video
Updated: May 12, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Molecular imaging probes for diagnosis and therapy evaluation of breast cancer
1Department of Translational Imaging, The Methodist Hospital Research Institute, Weill Cornell Medical College, 6670 Bertner Avenue, Houston, TX 77030, USA.
Abstract:
Breast cancer is a major cause of cancer death in women where early detection and accurate assessment of therapy response can improve clinical outcomes. Molecular imaging, which includes PET, SPECT, MRI, and optical modalities, provides noninvasive means of detecting biological processes and molecular events in vivo. Molecular imaging has the potential to enhance our understanding of breast cancer biology and effects of drug action during both preclinical and clinical phases of drug development. This has led to the identification of many molecular imaging probes for key processes in breast cancer. Hormone receptors, growth factor receptor, and angiogenic factors, such as ER, PR, HER2, and VEGFR, have been adopted as imaging targets to detect and stage the breast cancer and to monitor the treatment efficacy. Receptor imaging probes are usually composed of targeting moiety attached to a signaling component such as a radionuclide that can be detected using dedicated instruments. Current molecular imaging probes involved in breast cancer diagnosis and therapy evaluation are reviewed, and future of molecular imaging for the preclinical and clinical is explained.
Insights
Molecular imaging enhances breast cancer detection and therapy assessment. This review covers current probes targeting hormone receptors (ER, PR), growth factors (HER2), and angiogenic factors (VEGFR) for improved patient outcomes.
Area of Science:
- Oncology
- Radiology
- Biochemistry
Background:
- Breast cancer remains a leading cause of cancer mortality in women, necessitating advancements in early detection and treatment response assessment.
- Molecular imaging offers noninvasive in vivo visualization of biological processes, crucial for understanding breast cancer biology and drug development.
- Key molecular targets in breast cancer include hormone receptors (ER, PR), growth factor receptors (HER2), and angiogenic factors (VEGFR).
Purpose of the Study:
- To review current molecular imaging probes used in breast cancer diagnosis and therapy evaluation.
- To explore the potential of molecular imaging in enhancing the understanding of breast cancer biology and drug action.
- To discuss the future directions of molecular imaging in both preclinical and clinical settings for breast cancer.
Main Methods:
- Review of existing literature on molecular imaging techniques (PET, SPECT, MRI, optical) and probes for breast cancer.
- Identification and categorization of molecular imaging probes based on their targeting moieties and signaling components.
- Analysis of the application of these probes in detecting, staging, and monitoring treatment efficacy in breast cancer.
Main Results:
- Various molecular imaging probes targeting ER, PR, HER2, and VEGFR have been developed and utilized.
- These probes aid in early breast cancer detection, staging, and assessment of treatment response.
- Molecular imaging provides insights into drug effects during preclinical and clinical development.
Conclusions:
- Molecular imaging is a powerful tool for advancing breast cancer diagnosis and treatment monitoring.
- Continued development of novel imaging probes will further improve patient outcomes.
- The integration of molecular imaging in drug development pipelines is essential for personalized medicine approaches in breast cancer care.
